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Background and Purpose: To describe the final results of the TARGET Registry, a
multicenter, real-world study of patients with intracranial aneurysms treated with new
generation TARGET Coils.
Methods: The TARGET Registry is a prospective, single-arm study with independent
medical event monitoring and core-lab adjudication. Patients with de novo intracranial
aneurysmswere embolizedwith either TARGET-360◦ or helical coils in 12 US centers. The
primary outcome was aneurysm packing density (PD), which was assessed immediately
post-procedure. The secondary outcomes were immediate and long-term aneurysm
occlusion rate using the Raymond Scale, and independent functional outcome using
the modified Rankin Scale (mRS). A secondary analysis investigated the influence of the
use of 100% 360-complex coils on clinical and angiographic outcomes.
Results: 148 patients with 157 aneurysms met the inclusion and exclusion criteria.
58 (39.2%) patients with ruptured and 90 (61.8%) with unruptured aneurysms were
treated using TARGET 360◦, helical Coils, or both. Median age was 58.3 (IQR 48.1–67.4),
73% female, and 71.6% were Caucasian. Median follow-up time was 5.9 (IQR 4.0–6.9)
months. The majority were treated with TARGET 360-coils (63.7%), followed by mixed
and helical coils only. Peri-procedural morbidity and mortality was seen in 2.7% of
patients. A good outcome at discharge (mRS 0–2) was seen in 89.9% of the full cohort,
and in 84.5 and 93.3% in the ruptured and unruptured patients, respectively. The median
packing density was 28.8% (IQR 20.3–41.1). Long-term complete and near complete
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occlusion rate was seen in 90.4% of aneurysms and complete obliteration was seen in
66.2% of the aneurysms. No significant difference in clinical and angiographic outcomes
were noted between the pure 360-complex coiling vs. mixed 360-complex/Helical coiling
strategies. In a multivariate analysis, predictors for long-term aneurysm occlusion were
aneurysm location, immediate occlusion grade, and aneurysm size. The long-term
independent functional outcomewas achieved in 128/135 (94.8%) patients and all-cause
mortality was seen in 3/148 (2%) patients.
Conclusion: In the multicenter TARGET Registry, two-thirds of aneurysms achieved
long-term complete occlusion and 91.0% achieved complete or near complete occlusion
with excellent independent functional outcome.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT01748903
Keywords: aneurysm, coiling, ruptured aneurysm, occlusion, target coils, target registry, SAH
INTRODUCTION
Although the use of flow diverters and adjunctive devices has
increased in recent years, detachable coils remain the mainstay
approach in the endovascular treatment of intracranial
aneurysms (1–5). In a study of unruptured intracranial
aneurysms, ∼60% of anterior circulation aneurysms were
6mm or less, with 17% prevalence of aneurysms sizes between
1–3mm and 43% in 4–6mm in size range (6). These frequently
encountered small intracranial aneurysms (≤6mm) are
primarily treated with aneurysm coiling with or without
adjunctive devices. Complex coil shapes and 2D helical coils
are routinely used to achieve high packing density, complete
aneurysm occlusion, and enable the treatment of complex-
shaped aneurysms (7). These coil types can be used together
in a complementary approach to achieve greater aneurysm
occlusion. Previous studies comparing complex-shaped coils to
2D or helical coils are limited. In a matched-pair, case-control
study, the use of 3D complex coils as the initial framing coil was
associated with better packing density and long-term aneurysm
occlusion (7).
The TARGET Intracranial Aneurysm Coiling (TARGET)
Registry was a prospective, investigator-initiated, non-
randomized, multicenter study with independent clinical
event and core-lab adjudication, which aimed to collect real-
world data on the use of Target R© 360◦ and Target R© helical coils
for the embolization of ruptured or unruptured intracranial
aneurysms. Here, we present the peri-procedural and long-term
safety and occlusion efficacy results from the TARGET Registry.
METHODS
Study Design
The prospective, multicenter TARGET Registry included
ruptured or unruptured saccular intracranial aneurysms, which
were treated with Target 360◦ coils only (360◦ group) or both
Target 360◦ and Helical coils (Mixed group) (ClinicalTrials.gov
Identifier: NCT01748903). A total of 12 clinical sites within the
United States participated in the TARGET Registry. All sites
received local Institutional Review Board approval for the study.
Mercy St. Vincent Medical Center, Toledo, Ohio served as the
coordinating center for TARGET Registry.
Study Population
Patients were eligible for enrollment in the TARGET Registry
if the following criteria were met: (1) Age 18 years or
older, (2) Previously untreated saccular intracranial aneurysm,
unruptured, or ruptured, suitable for embolization with coils,
(3) Hunt and Hess Score of 3 or less, (4) Premorbid
mRS of 3 or less, (5) Patient or patient’s legally authorized
representative can provide written informed consent, and (6)
The patient is willing to and can comply with study follow-
up requirements. Patients were excluded from enrollment if
they met any of the following: (1) Less than 18 years of
age, (2) Patients with intracranial aneurysms other than the
target aneurysm that has undergone treatment ≤1 year from
enrollment in the study, (3) Dissecting target aneurysm, (4)
Patients in whom the target aneurysm will be treated with
coils other than Stryker Target R© 360◦ and Target R© Helical
coils, (5) Target aneurysm is fusiform, (6) Patients in which
the target aneurysm cannot be coiled in one procedure (i.e.,
staged procedure).
Study Procedures
Standard local institutional trans-arterial coiling techniques and
anesthesia approach were used at each site per the participating
interventionalist preference. Given that the secondary intention
of this study was to assess the results of aneurysms treated with
complex shape Target R© 360◦ coils only vs. Mixed 360◦ and/or
Target R© 2D Helical coils, investigators were encouraged to use
the same coil type for framing, filling, and finishing, if possible.
Use of adjunctive devices was permitted. Long-term follow-
up occurred at 3–9 months (per each site’s standard of care) and
included imaging of the target aneurysm (DSA or MRA) and
assessment of clinical outcome using the modified Rankin Scale
(mRS). All source data from case report forms were entered into
a secure database (REDCAP) and managed/monitored by the
central coordinating center.
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Clinical and Imaging Adjudication
An independent medical monitor reviewed all adverse events
(AEs) and Serious AEs (SAEs) for the study and adjudicated
relatedness to the underlying diseases, procedure, or study device.
For determination of aneurysm occlusion outcome, de-
identified vascular angiographic images (DSA and MRA) were
sent to the imaging core lab for adjudication of the modified
Raymond aneurysm occlusion grade (8, 9) immediately post-
procedure and on the long-term imaging follow-up. The
progression to complete occlusion or regression to aneurysm
recurrence and recanalization was also assessed by the core
imaging lab.
Study Outcomes
The primary study outcomes was aneurysm packing density at
immediate post-procedure. Secondary study outcomes included:
aneurysm re-access rate (Microcatheter kick-back rate), time
of fluoroscopic exposure, overall procedure time, aneurysm
recurrence at follow-up, aneurysm re-treatment rate, aneurysm
bleed and re-bleed rate, treatment related morbidity and
mortality, clinical outcome (mRS) at baseline and follow-
up, and peri/post-procedural adverse events related to device
and/or procedure.
A secondary analysis was performed comparing technical and
clinical endpoints Target 360◦ and Target Helical coils.
Statistical Methods
Categorical data are presented for all patients as a percentage
(n = frequency count) and as a percentage by treatment
group (rounded to the nearest whole number). Continuous
data are expressed as mean (SD) or median (IQR) if non-
normally distributed. Categorical factors were compared between
treatment groups with Chi-square tests or Fisher’s Exact tests
when cell sizes were small. Continuous data were compared
between treatment groups with Student T-test or MannWhitney
for non-normal data. Logistic regression was used to calculate the
odds ratio for poor outcome (mRS 3–6). Factors associated with
packing density were analyzed in univariable analysis with Mann
Whitney test and Spearman correlation. All p-values were two-
tailed. A p-value < 0.05 was considered statistically significant.
Data were analyzed with SAS and JMP v. 13 (Cary, NC).
This study was not designed to detect differences of a certain
magnitude between groups with an apriori power calculation.
Therefore, the lack of a significant p-value (i.e., “no significant
difference”) may be due to small sample size.
RESULTS
From January 2013 to May 2014, 150 patients with 159 ruptured
or unruptured aneurysms were prospectively enrolled in the
TARGET Registry. Of the 150 patients, 2 were excluded due to
a Hunt & Hess score of 4 and the use of non-TARGET coils. Data
from 148 patients with 157 aneurysms were included in the per-
protocol analysis (100 in the pure 360◦ coiling group and 57 in
the mixed coiling group 360◦ and 2D helical coiling).













Age, median (IQR) 58.3 (48.1–67.4) 57.9 (48–66.9) 59.1 (48.4–70.4) 0.5
Gender, female 73.0% (108) 75% (69) 69.6% (39) 0.48
Race 0.21
White/Caucasian 71.6% (106) 76.1% (70) 64.3% (36)
Black/African
American
10.8% (16) 7.6% (7) 16.1% (9)
Hispanic/Latino 13.5% (20) 14.1% (13) 12.5% (7)
Other 4.1% (6) 2.2% (2) 7.2% (4)
Medical history
Headache/migraine 44.6% (66) 48.9% (45) 37.5% (21) 0.19
Previous stroke
Hemorrhagic 9.5% (14) 7.6% (7) 12.5% (7) 0.53
Ischemic 9.5% (14) 6.5% (6) 14.3% (8) 0.16
Transient ischemic
attack




17.6% (26) 20.6% (19) 12.5% (7) 0.39
Diabetes 16.9% (25) 17.4% (16) 16.1% (9) 0.72
Hypertension 59.5% (88) 62.0% (57) 55.4% (31) 0.50
Smoking 48.0% (71) 45.7% (42) 51.8% (29) 0.45
Arteriovenous
malformation
1.4% (2) 2.2% (2) 0% (0) 0.48
Polycystic kidney
disease
0.7% (1) 1.1% (1) 0% (0) 0.29
Hyperlipidemia 37.8% (56) 35.9% (33) 41.1% (23) 0.82
Seizure 6.8% (10) 6.5% (6) 7.1% (4) 0.98
Previously treated
aneurysm
7.0% (10) 7% (6) 8% (4) 0.74
Premorbid mRS∧ 0.17
0 87.8% (130) 91.3% (84) 82.1% (46)
1 8.1% (12) 7.6% (7) 8.9% (5)
2 1.4% (2) 0% (0) 3.6% (2)
3 2.0% (3) 1.1% (1) 2.6% (2)
*One patient excluded for coils other than TARGET were used; and a second patient
excluded due to baseline H&H of 4.∧mRS, modified Rankin’s Scale.
Overall TARGET Cohort
Baseline
Baseline demographics of the overall TARGET Cohort are
summarized in Table 1. Median age was 58.3 (48.1–67.4) years,
73% were female, and 71.6% were Caucasian. Of the 148 patients,
39.2% presented with a ruptured intracranial aneurysm (Table 2).
The median maximum aneurysm size was 5.6mm (IQR 4.4–
7.9mm) and neck diameter was 3.2mm (IQR 2.2–4.2mm).
Most aneurysms were in the anterior circulation (79.1%), with
37.8, 25.0, and 16.9%, in the internal carotid artery, anterior
communicating artery, and middle cerebral artery, respectively.
Stent-assisted and balloon-assisted coiling was used in 33.8 and
25.7% of patients, respectively. Median packing density in the
overall TARGET cohort was 28.8% (IQR 20.3–41%) (Table 3).
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0 64.9% (96) 65.2% (60) 64.3% (36) 1.0
1 22.3% (33) 22.8% (21) 21.4% (12) 1.0
2 8.1% (12) 7.6% (7) 8.9% (5) 0.77
3 2.7% (4) 2.2% (2) 3.6% (2) 0.63
4 1.4% (3) 1.1% (1) 1.8% (2) 0.56




5.6 (4.4–7.9) 5.5 (4.5–7.5) 5.6 (4.2–8.0) 0.52
Aneurysm neck
diameter, mm
3.2 (2.2–4.2) 3.0 (2.1–4.4) 3.3 (2.5–4.2) 0.78





Multiple aneurysms 6.1% (9) 5.4% (5) 7.1% (4) 0.67
Side, Right 52.7% (78) 46.7% (43) 62.5% (35) 0.09
Left 39.2% (58) 42.4% (39) 33.9% (19) 0.39
Midline 8.1% (12) 10.9% (10) 3.6% (2) 0.13
Location
ICA 37.8% (56) 40.2% (37) 33.9% (19) 0.60
ACA 25.0% (37) 19.6% (18) 33.9% (19) 0.08
MCA 16.9% (25) 15.2% (14) 19.6% (11) 0.50
Basilar 15.2% (23) 19.6% (18) 8.9% (5) 0.10
Vertebral 4.1% (6) 4.4% (4) 3.6% (2) 1.0
Extradural ICA 0.7% (1) 1.1% (1) 0% (0) 1.0
Bifurcation 58.8% (87) 55.4% (51) 64.3% (36) 0.31
Anterior 79.1% (117) 73.9% (68) 87.5% (49) 0.09
Shape, irregular 58.8% (87) 57.6% (53) 60.7% (34) 0.73
Daughter Sac 5.4% (8) 4.3% (4) 7.1% (4) 0.48
Multilobulated 17.6% (26) 17.4% (16) 17.8% (10) 1.0
Subarachnoid
hemorrhage
Ruptured status 39.2% (58) 40.2% (37) 37.5% (21) 0.74
Hunt & Hess scale
I 17.2% (10) 24.3% (9) 4.8% (1) 0.09
II 51.7% (30) 51.3% (19) 52.4% (11) 1.0
III 31.0% (18) 24.3% (9) 42.9% (9) 1.0
Technical features
Stent-assisted coiling 33.8% (50) 33.7% (31) 33.9% (19) 0.98
Stent type
Cordis 0.7% (1) 1.1% (1) 0% (0)
Enterprise 5.4% (8) 3.3% (3) 8.9% (5)
Neuroform 26.4% (39) 28.3% (26) 23.2% (13)
Pipeline 1.4% (2) 1.1% (1) 1.8% (1)
Balloon-assisted coiling 25.7% (38) 22.8% (21) 30.3% (17) 0.31
Balloon type
Hyperform 1.4% (2) 1.1% (1) 1.8% (1)
Hyperglide 5.4% (8) 2.2% (2) 10.7% (6)
Scepter XC 2.0% (3) 2.2% (2) 1.8% (1)
Transform 16.9% (25) 16.3% (15) 17.9% (10)
Access site, Right 84.5% (125) 89.1% (82) 76.8% (43) 0.06
Left 6.8% (10) 3.3% (3) 12.5% (7) 0.04
Right & left 8.8% (13) 7.6% (7) 10.7% (6) 0.56
Immediate complete or near complete occlusion
(modified Raymond grade I-II) was achieved in 91.7%
(144/157) of the treated aneurysms and 8.3% (13/157)
had residual dome filling (Raymond grade III). Grade I
(complete occlusion) was achieved in 105/157 (66.9%) of the
treated aneurysms.
Microcatheter kick-back (requiring re-accessing of
the aneurysm) occurred in 20.3%. The symptomatic
complication rate within 24 h was 2.7% (4/148). Intra-
operative perforation (IOP) occurred in 2.7% of the patients
(2/4 were symptomatic). Peri-procedural mortality rate was
0.7% (1/148). Thrombo-embolic events (TEEs) occurred
in 4.7% (7/148) of the patients with 2/7 patients or 1.4%
being symptomatic.
Good clinical outcome (mRS 0–2) at discharge was seen in
89.9%. Most patients (73%) were discharged home, while one
patient (0.7%) expired in the hospital.
Full Cohort Long-Term Outcome
Median follow-up was 5.9 months (IQR: 4–6.9 months) in
the overall cohort, with 86.0% (135/157) of the aneurysms
had available follow-up angiographic occlusion data and 86.6%
(136/157) with clinical outcome reported. At follow-up, 90.4%
(123/136) of aneurysms had complete or near complete
occlusion. Complete occlusion (RR scale I) was achieved in
66.2% (90/136). At follow-up, 84.8% of patients had a better
or stable occlusion status. The retreatment rate in the overall
cohort was 2.4%. The rate of good clinical outcome was
94.8%. A total of three deaths occurred including a peri-
procedural death (2% mortality rate), one related to IOP, one
unrelated death, and one unknown cause during the follow up
period (Table 3).
360 Coiling and Mixed Coiling Groups
A secondary analysis comparing 100% 360◦ coils (100
aneurysms) to a mixed approach of both complex 360◦
shape and 2D helical coils (57) demonstrated no significant
difference in the baseline variables between the two
groups (Table 1).
The median maximum aneurysm size and neck diameter were
similar between the two groups, with no signification difference
in the aneurysmal location or relation to a branching point
(bifurcation vs. sidewall) (Table 2).
Median packing density was 27.7% (IQR 21.2–41.1) in the
360◦ coiling group vs. 31.3% (IQR 19–41.1) in the Mixed Coiling
group (p = 0.3) (Table 3). No difference was observed in the
immediate post-treatment occlusion rates or rates of good clinical
outcome between the two subgroups (Table 3).
At follow-up, no significant difference was shown in the rates
of complete to near complete occlusion (Table 3). The complete
occlusion rate was similar between the two groups at 64.6 and
70.5% in the 360◦ and Mixed groups, respectively (p = 0.5,
Table 3). No statistical difference was seen in the re-treatment
rate between the two cohorts (2.5 and 2.1%, p= 0.9).
The rate of good clinical outcome (mRS 0–2) at follow-up was
97.6% in the 360◦ group vs. 90.4% in the Mixed group (Table 3).
Frontiers in Neurology | www.frontiersin.org 4 July 2019 | Volume 10 | Article 737
Zaidat et al. Target Intracranial Aneurysm Registry









Packing density % 28.8% 27.7% 31.3% 0.30
Median IQR (20.3%−41.1%) (21.4%−41.1%) (19.9%−41.1%)
IMMEDIATE OCCLUSION RAYMOND SCALE PER CORE LAB
Raymond class I & II 91.7% 90.2% 90.9% 1.0
Raymond class I 66.9% 66.3% 65.5% 1.0
DISCHARGE CLINICAL FUNCTIONAL ASSESSMENT (MRS)
mRS 0–2 89.9% (133) 92.4% (85) 85.7% (48) 0.26
mRS 0–1 84.5% (125) 88.0% (81) 78.6% (44) 0.16
DISCHARGE DISPOSITION
Acute rehabilitation 24.3% (36) 23.9% (22) 25% (14) 0.34
Home 73.0% (108) 72.8% (67) 73.2% (41)
Extended care facility 2.0% (3) 2.2% (2) 1.8% (1)
Expired in hospital 0.7% (1) 1.1% (1) 0% (0)
PROCEDURAL TECHNICAL AND CLINICAL OUTCOME
Symptomatic morbidity and mortality (up to discharge) 2.7% (4)
Mortality 0.7% (1)
Any intraoperative perforation 2.7% (4) 2.2% (2) 3.6% (2) 0.63
Symptomatic 1.4% (2) 1.1% (1) 1.8% (1)
Any thromboembolic event 4.7% (7) 4.3% (4) 5.4% (3) 1.0
Symptomatic 1.4% (2) 1.1% (1) 1.8% (1)
LONG-TERM OUTCOMES:
Raymond class I & II 90.4% 89.9% 90.9% 0.80
Raymond class I 66.2% 64.6% 70.5% 0.50
RETREATMENT RATE
Retreatment rate 2.4% (3) 2.5% (2) 2.1% (1) 0.9
OCCLUSION PROGRESSION PER CORE LAB
Progressive occlusion 16.8% (21) 18.8 (15) 12.8 (6) 0.46
Stable 68.0% (87) 67.5 (54) 70.2 (33) 0.84
Recanalization 15.2% (19) 13.8 (11) 17.0 (8) 0.62
LONG-TERM CLINICAL FUNCTIONAL ASSESSMENT (MRS): 135 (83, 52)
mRS 0–2 94.8% (128) 97.6% (81) 90.4% (47) 0.52
mRS 0–1 93.3% (126) 96.4% (80) 88.5% (46) 0.49
Adverse event since discharge 3.1% (4) 2.5% (2) 4.3% (2) 0.64
Predictors of Long-Term Aneurysm
Occlusion
After adjusting for age, aneurysm size, bifurcation location,
packing density, ruptured status, and use of 100% 360◦ coils:
aneurysm size, bifurcation location, and immediate occlusion
status remained independent predictors of long-term complete
occlusion on digital subtraction angiography (Table 4).
Illustrative Case
A middle age woman presented with a severe headache and neck
stiffness. A plain head CT scan showed diffuse subarachnoid
hemorrhage. The CT angiogram demonstrated 5mm right
posterior communicating artery aneurysm. This was treated with
100% 360◦ Target R© coils (360◦ Ultrasoft coils: 4mm× 8 cm, 2×
6, 360◦ NanoTM coils: 1.5 × 4, 1.5 × 4, 1 × 3, 1 × 2, and 1 × 2),
with complete occlusion (Figure 1).
DISCUSSION
Since the publications of the randomized international (ISAT
trial) and US coiling vs. clipping (BRAT) clinical trials (10, 11),
coiling technology has continued to evolve with softer and
smaller coils allowing for safer and more complete treatment
of intracranial aneurysms. The recent literature comparing bare
platinum coils vs. bioactive material coated or modified coils
to enhance aneurysm occlusion did not yield promising results
for bioactive technology (12–16). The Matrix and Platinum
Science (MAPS), Cerecyte vs. bare platinum, and hydrogel-
coated vs. bare platinum coils randomized clinical trials showed
no significant difference in the primary outcomes between
bioactive and bare platinum coils (12–14). As bare platinum coils
remain the mainstay therapy for intracranial aneurysms, interest
has grown in enhancing their mechanical attributes tomake them
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TABLE 4 | Multivariable predictors of long-term aneurysm complete occlusion.
Term Estimate Std. error ChiSquare Prob > ChiSq Lower 95% Upper 95%
Intercept 2.66 2.36 1.27 0.26 −1.87 7.45
Age 0.00 0.03 0.00 0.95 −0.06 0.06
>65 years of age 0.35 0.41 0.72 0.40 −0.45 1.18
Bifurcation −0.64 0.25 6.54 0.01* −1.15 −0.16
Ruptured 0.42 0.26 2.64 0.10 −0.08 0.94
Aneurysm size −0.25 0.13 3.88 0.05* −0.52 −0.01
Immediate occlusion −1.83 0.45 16.70 <0.0001* −2.80 −1.02
Packing density −0.03 0.03 1.41 0.23 −0.09 0.02
100% 360 coils 0.26 0.25 1.13 0.29 −0.22 0.76
*p ≤ 0.05.
FIGURE 1 | Illustrative case example demonstrating the 100% 360 coiling case in a patient with subarachnoid hemorrhage.
safer, softer, easier to deploy, and therefore, better able to treat
smaller aneurysms. The Target coils are the newest iteration of
the GDC coils with a softer distal push wire and more supportive
proximal wire, with softer and smaller coil diameters.
The TARGET Registry demonstrated complete and near
complete occlusion rates in more than 90% of aneurysms at
follow-up, with low retreatment rates with TARGET coils. The
peri-procedural mortality rate was 0.7% and all-cause long-term
mortality rate was 2%. At follow-up, 82.8% of ruptured cases
had a mRS ≤ 2, compared to 96% in unruptured cases. These
results are comparable to the ISAT and BRAT trial ruptured
cohorts, which demonstrated rates of 76.5 and 77%, respectively
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(10, 11). The slightly better outcome in our ruptured cohort may
be due to the differences between the TARGET Registry ruptured
population vs. the BRAT and ISAT populations, as well as the
smaller sample size in our registry.
The rate of successful occlusion and low retreatment rate are
also consistent with other prospective coiling registries using
different manufacturer coils. Hirsch et al. in their TrufillTM DCS
Orbit platinum coils (Cerenovous, CA) aneurysm registry noted
a near complete occlusion rate of 84% with a 5% retreatment
rate (17). Similarly, a complete to near complete occlusion rate
was seen in 88.4% of the cases in 599 aneurysms treated with
Hydrosoft coils R© (Microvention CA) with 1.8% rate of morbidity
andmortality (18). In the AxiumMicroFx Coils (Medtronic, CA)
registry, the median follow up was 5 months and revealed 90% of
the ruptured aneurysms, and 93.3% of the unruptured aneurysms
had Raymond Scale I or II occlusion, with 2% mortality rate
occurring exclusively in cases of ruptured aneurysms (19).
Coil Shape and Outcomes
The main advantages of 3D complex shaped coils are their ability
to provide coil mass stability within the aneurysm sac and to
allow for coiling of relatively wide-neck aneurysms (20). In a
160 patient study using one or more 3D coils to compare wide
neck vs. narrow neck aneurysm groups, the performance of a
mixed strategy was similar in both groups regardless of the neck
size (20). The 3D framing approach for wide neck aneurysms
yielded an angiographic occlusion rate of 68% with morbidity
and mortality of 4%, which compared well to the narrow neck
aneurysms (20).
However, other authors have reported the value of complex
shape coils for improving aneurysm packing density, reducing
coils compaction, and potentially increasing the rate of complete
aneurysm obliteration with subsequent reduction in the rate of
aneurysm re-treatment. Lang et al. demonstrated higher packing
density using the 3D coils vs. 2D coils (30 vs. 23%, respectively).
In the TARGETRegistry, we evaluated two different strategies,
100% complex shape coils for framing, filling and finishing
vs. mixed approach of both complex and helical coils. Our
sample size was small and yielded no significant difference
between the two approaches in reference to packing density
and occlusion rate. These results may also be related to the
fact that the coil choice was according to each operator’s
preference, whichmay have biased the results. However, we could
not identify any significant difference between the two groups
when we compared the baseline variables. With advances in
complex shape technology, comparing a 100% approach vs. a
mixed approach likely requires a larger sample size. Our results
suggest that both approaches are acceptable in their safety and
efficacy profile.
Study Limitations
There are several limitations to this study, which include small
sample size, the lack of true randomization vs. based on the site
and operator preferences, and long-term outcome of less than
a year.
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